Identification

Name
Tranilast
Accession Number
DB07615
Type
Small Molecule
Groups
Approved, Investigational
Description

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Structure
Thumb
Synonyms
  • N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  • tranilast
  • tranilastum
External IDs
MK 341 / MK-341 / MK341
International/Other Brands
Rizaben
Categories
UNII
HVF50SMY6E
CAS number
53902-12-8
Weight
Average: 327.3313
Monoisotopic: 327.110672659
Chemical Formula
C18H17NO5
InChI Key
NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
IUPAC Name
2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
SMILES
COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC

Pharmacology

Indication

For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UHematopoietic prostaglandin D synthase
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding can be increased when Tranilast is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding can be increased when Tranilast is combined with (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Tranilast is combined with 4-hydroxycoumarin.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Tranilast.Investigational
AbciximabTranilast may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolThe risk or severity of bleeding can be increased when Tranilast is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Tranilast.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Acetylsalicylic acid.Approved, Vet Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Tranilast.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Tranilast.Investigational
AlcuroniumTranilast may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Tranilast.Approved, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Tranilast is combined with Aloxiprin.Experimental
AlteplaseTranilast may increase the anticoagulant activities of Alteplase.Approved
AmediplaseTranilast may increase the anticoagulant activities of Amediplase.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Tranilast can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Tranilast.Approved
AmobarbitalThe metabolism of Tranilast can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Tranilast.Approved
Amphotericin BTranilast may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Tranilast can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideTranilast may increase the anticoagulant activities of Anagrelide.Approved
AncrodTranilast may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Tranilast.Investigational
AnistreplaseTranilast may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanThe risk or severity of bleeding can be increased when Tranilast is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Tranilast can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Tranilast is combined with Apixaban.Approved
AprepitantThe serum concentration of Tranilast can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe risk or severity of bleeding can be increased when Tranilast is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTranilast may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tranilast.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Tranilast.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Tranilast.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Tranilast.Approved
AstaxanthinTranilast may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Tranilast can be decreased when combined with Atazanavir.Approved, Investigational
AtracuriumTranilast may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateTranilast may increase the neuromuscular blocking activities of Atracurium besylate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Tranilast is combined with Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Tranilast can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tranilast can be increased when combined with Barbital.Illicit
BemiparinThe risk or severity of bleeding can be increased when Tranilast is combined with Bemiparin.Approved, Investigational
BeraprostBeraprost may increase the antiplatelet activities of Tranilast.Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Tranilast.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Tranilast.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tranilast.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Tranilast.Approved
BivalirudinThe risk or severity of bleeding can be increased when Tranilast is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Tranilast can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Tranilast can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Tranilast.Approved, Investigational
BrinaseTranilast may increase the anticoagulant activities of Brinase.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Tranilast.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Tranilast.Investigational
BuflomedilTranilast may increase the antiplatelet activities of Buflomedil.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Tranilast.Investigational
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Tranilast.Approved
ButylphthalideTranilast may increase the antiplatelet activities of Butylphthalide.Investigational
Calcium AcetateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Phosphate.Approved
CangrelorCangrelor may increase the antiplatelet activities of Tranilast.Approved
CarbamazepineThe metabolism of Tranilast can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tranilast is combined with Carbaspirin calcium.Experimental, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tranilast.Approved, Investigational
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Tranilast.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Tranilast.Approved, Investigational, Nutraceutical, Vet Approved
CeritinibThe serum concentration of Tranilast can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of bleeding can be increased when Tranilast is combined with Certoparin.Approved, Investigational
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Tranilast.Approved, Investigational, Vet Approved
CilostazolCilostazol may increase the antiplatelet activities of Tranilast.Approved, Investigational
CimetidineThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved, Investigational
CisatracuriumTranilast may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramCitalopram may increase the antiplatelet activities of Tranilast.Approved
ClarithromycinThe metabolism of Tranilast can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.Approved
CloricromenTranilast may increase the antiplatelet activities of Cloricromen.Experimental
ClorindioneThe risk or severity of bleeding can be increased when Tranilast is combined with Clorindione.Experimental
ClotrimazoleThe metabolism of Tranilast can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Tranilast.Approved
CobicistatThe metabolism of Tranilast can be decreased when combined with Cobicistat.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Tranilast is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Tranilast.Approved, Investigational
CrizotinibThe metabolism of Tranilast can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Tranilast can be decreased when combined with Curcumin.Approved, Investigational
CyclosporineThe metabolism of Tranilast can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTranilast may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Tranilast can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinTranilast may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTranilast may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Tranilast can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Tranilast.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Tranilast.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Tranilast.Investigational
DarexabanThe risk or severity of bleeding can be increased when Tranilast is combined with Darexaban.Investigational
DarunavirThe metabolism of Tranilast can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Tranilast.Approved, Investigational
DeferasiroxThe serum concentration of Tranilast can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideTranilast may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe metabolism of Tranilast can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Dersalazine.Investigational
DesirudinThe risk or severity of bleeding can be increased when Tranilast is combined with Desirudin.Approved
DesmoteplaseTranilast may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Tranilast.Approved, Investigational
DexamethasoneThe serum concentration of Tranilast can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranThe risk or severity of bleeding can be increased when Tranilast is combined with Dextran.Approved, Investigational, Vet Approved
DicoumarolTranilast may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflunisal.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Tranilast.Approved, Investigational
DiltiazemThe metabolism of Tranilast can be decreased when combined with Diltiazem.Approved, Investigational
DiphenadioneThe risk or severity of bleeding can be increased when Tranilast is combined with Diphenadione.Experimental
DipyridamoleDipyridamole may increase the antiplatelet activities of Tranilast.Approved
DitazoleThe risk or severity of bleeding can be increased when Tranilast is combined with Ditazole.Approved, Withdrawn
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Tranilast.Approved
DoxacuriumTranilast may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Tranilast.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Tranilast.Approved, Investigational
DoxycyclineThe metabolism of Tranilast can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Tranilast.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Tranilast.Approved, Vet Approved
Drotrecogin alfaTranilast may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Tranilast.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Tranilast.Approved
Edetic AcidThe risk or severity of bleeding can be increased when Tranilast is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding can be increased when Tranilast is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Tranilast.Approved
EnoxaparinThe risk or severity of bleeding can be increased when Tranilast is combined with Enoxaparin.Approved
EnzalutamideThe serum concentration of Tranilast can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolEpoprostenol may increase the antiplatelet activities of Tranilast.Approved
EptifibatideEptifibatide may increase the antiplatelet activities of Tranilast.Approved, Investigational
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Tranilast.Approved
ErythromycinThe metabolism of Tranilast can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Tranilast.Approved, Investigational
Ethyl biscoumacetateThe risk or severity of bleeding can be increased when Tranilast is combined with Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Tranilast can be decreased when it is combined with Etravirine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Tranilast.Experimental
Ferulic acidThe risk or severity of bleeding can be increased when Tranilast is combined with Ferulic acid.Experimental
FibrinolysinTranilast may increase the anticoagulant activities of Fibrinolysin.Investigational
FluconazoleThe metabolism of Tranilast can be decreased when combined with Fluconazole.Approved, Investigational
FluindioneThe risk or severity of bleeding can be increased when Tranilast is combined with Fluindione.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Tranilast.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Tranilast.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Tranilast.Experimental
FluvoxamineFluvoxamine may increase the antiplatelet activities of Tranilast.Approved, Investigational
FondaparinuxTranilast may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
FosamprenavirThe metabolism of Tranilast can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tranilast can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tranilast.Approved, Investigational
Fusidic AcidThe serum concentration of Tranilast can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe risk or severity of bleeding can be increased when Tranilast is combined with Gabexate.Investigational
GallamineTranilast may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideTranilast may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GlucosamineGlucosamine may increase the antiplatelet activities of Tranilast.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tranilast.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Tranilast is combined with Guacetisal.Experimental
HeparinThe risk or severity of bleeding can be increased when Tranilast is combined with Heparin.Approved, Investigational
HexobarbitalThe metabolism of Tranilast can be increased when combined with Hexobarbital.Approved
HydroxytyrosolTranilast may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.Approved
IbudilastIbudilast may increase the antiplatelet activities of Tranilast.Approved, Investigational
Icosapent ethylTranilast may increase the antiplatelet activities of Icosapent ethyl.Approved, Investigational, Nutraceutical
IdelalisibThe metabolism of Tranilast can be decreased when combined with Idelalisib.Approved
IdraparinuxThe risk or severity of bleeding can be increased when Tranilast is combined with Idraparinux.Investigational
IfetrobanTranilast may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Tranilast.Approved
IloprostTranilast may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Tranilast can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Tranilast.Approved
IndalpineIndalpine may increase the antiplatelet activities of Tranilast.Investigational, Withdrawn
IndinavirThe metabolism of Tranilast can be decreased when combined with Indinavir.Approved
IndobufenTranilast may increase the antiplatelet activities of Indobufen.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Tranilast.Withdrawn
IsavuconazoleThe serum concentration of Tranilast can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Tranilast can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Tranilast.Approved
IsoniazidThe metabolism of Tranilast can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Tranilast can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tranilast can be increased when it is combined with Ivacaftor.Approved
KetanserinTranilast may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Tranilast can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Tranilast.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Tranilast.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Tranilast.Approved
LepirudinThe risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.Approved
LetaxabanThe risk or severity of bleeding can be increased when Tranilast is combined with Letaxaban.Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Tranilast.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Tranilast.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Tranilast.Approved
LinsidomineTranilast may increase the antiplatelet activities of Linsidomine.Experimental
LopinavirThe metabolism of Tranilast can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Tranilast can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Tranilast can be decreased when combined with Lovastatin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tranilast.Approved, Investigational
LuliconazoleThe serum concentration of Tranilast can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Tranilast can be increased when combined with Lumacaftor.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Tranilast.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Tranilast.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Tranilast.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Tranilast.Approved, Investigational
MelagatranThe risk or severity of bleeding can be increased when Tranilast is combined with Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Mesalazine.Approved
MethohexitalThe metabolism of Tranilast can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Tranilast.Approved, Investigational
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Tranilast.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.Approved
MetocurineTranilast may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideTranilast may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MibefradilThe metabolism of Tranilast can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Tranilast can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Tranilast can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Tranilast.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tranilast.Approved, Vet Approved
MitotaneThe serum concentration of Tranilast can be decreased when it is combined with Mitotane.Approved
MivacuriumTranilast may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Tranilast can be decreased when it is combined with Modafinil.Approved, Investigational
NadroparinThe risk or severity of bleeding can be increased when Tranilast is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding can be increased when Tranilast is combined with Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Tranilast can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilTranilast may increase the antiplatelet activities of Naftopidil.Investigational
NaloxoneThe metabolism of Tranilast can be decreased when combined with Naloxone.Approved, Vet Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Tranilast.Approved, Withdrawn
NelfinavirThe metabolism of Tranilast can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Tranilast can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Tranilast can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Tranilast.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Tranilast.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Tranilast.Experimental
NilotinibThe metabolism of Tranilast can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the antiplatelet activities of Tranilast.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tranilast is combined with Nitroaspirin.Investigational
NitroprussideTranilast may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Tranilast.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.Approved, Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Tranilast.Approved, Investigational
OlaparibThe metabolism of Tranilast can be decreased when combined with Olaparib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Tranilast.Approved, Nutraceutical
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Tranilast.Experimental
OsimertinibThe serum concentration of Tranilast can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of bleeding can be increased when Tranilast is combined with Otamixaban.Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Tranilast.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Tranilast.Investigational, Withdrawn
PalbociclibThe serum concentration of Tranilast can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Tranilast.Approved
PancuroniumTranilast may increase the neuromuscular blocking activities of Pancuronium.Approved
ParnaparinThe risk or severity of bleeding can be increased when Tranilast is combined with Parnaparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Tranilast.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Tranilast.Experimental
PentobarbitalThe metabolism of Tranilast can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Tranilast.Approved, Investigational
PhenindioneThe risk or severity of bleeding can be increased when Tranilast is combined with Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Tranilast can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Tranilast.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Tranilast.Approved
PhenprocoumonThe risk or severity of bleeding can be increased when Tranilast is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Tranilast.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Phenyl aminosalicylate.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tranilast.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tranilast.Approved
PicotamideTranilast may increase the antiplatelet activities of Picotamide.Experimental
PipecuroniumTranilast may increase the neuromuscular blocking activities of Pipecuronium.Approved
PitolisantThe serum concentration of Tranilast can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Tranilast.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Tranilast.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Tranilast.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Tranilast.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tranilast.Approved, Vet Approved
PosaconazoleThe metabolism of Tranilast can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Tranilast.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding can be increased when Tranilast is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the antiplatelet activities of Tranilast.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Tranilast.Approved
PrimidoneThe metabolism of Tranilast can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Tranilast.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Tranilast.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Tranilast.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Tranilast.Approved, Investigational
Protein CTranilast may increase the anticoagulant activities of Protein C.Approved
Protein S humanThe risk or severity of bleeding can be increased when Tranilast is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Tranilast is combined with Protocatechualdehyde.Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Tranilast.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Tranilast.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Tranilast.Approved, Investigational
QuinineThe metabolism of Tranilast can be increased when combined with Quinine.Approved
RamatrobanTranilast may increase the antiplatelet activities of Ramatroban.Investigational
RapacuroniumTranilast may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Tranilast.Investigational
RelcovaptanTranilast may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Tranilast.Approved, Experimental, Investigational
ReteplaseTranilast may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding can be increased when Tranilast is combined with Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Tranilast.Approved
RifampicinThe metabolism of Tranilast can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Tranilast can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Tranilast can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Tranilast can be increased when combined with Rifaximin.Approved, Investigational
RimexoloneThe metabolism of Tranilast can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Tranilast.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Tranilast.Investigational
RitonavirThe metabolism of Tranilast can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanTranilast may increase the anticoagulant activities of Rivaroxaban.Approved
RocuroniumTranilast may increase the neuromuscular blocking activities of Rocuronium.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Tranilast can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Tranilast can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateTranilast may increase the antiplatelet activities of Sarpogrelate.Investigational
SaruplaseTranilast may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe metabolism of Tranilast can be increased when combined with Secobarbital.Approved, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Tranilast.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Tranilast.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Tranilast.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Tranilast.Approved, Vet Approved
SibutramineSibutramine may increase the antiplatelet activities of Tranilast.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Tranilast.Approved
SiltuximabThe serum concentration of Tranilast can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Tranilast can be increased when it is combined with Simeprevir.Approved
Sodium CitrateThe risk or severity of bleeding can be increased when Tranilast is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tranilast.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Tranilast.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Tranilast.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Tranilast.Approved
St. John's WortThe serum concentration of Tranilast can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Tranilast can be increased when it is combined with Stiripentol.Approved
StreptokinaseTranilast may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Tranilast.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Sulfasalazine.Approved
SulfinpyrazoneTranilast may increase the antiplatelet activities of Sulfinpyrazone.Approved
SulodexideTranilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tranilast.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Tranilast.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Tranilast can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Tranilast can be decreased when combined with Telithromycin.Approved
TenecteplaseTranilast may increase the anticoagulant activities of Tenecteplase.Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Tranilast.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Tranilast.Approved
TesmilifeneTranilast may increase the antiplatelet activities of Tesmilifene.Investigational
ThiamylalThe metabolism of Tranilast can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tranilast can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Tranilast.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Tranilast.Approved, Withdrawn
TicagrelorTranilast may increase the antiplatelet activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the antiplatelet activities of Tranilast.Approved
TinzaparinTranilast may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding can be increased when Tranilast is combined with Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Tranilast.Approved
TipranavirTipranavir may increase the antiplatelet activities of Tranilast.Approved, Investigational
TirofibanTirofiban may increase the antiplatelet activities of Tranilast.Approved
TocilizumabThe serum concentration of Tranilast can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneThe risk or severity of bleeding can be increased when Tranilast is combined with Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Tranilast.Approved, Vet Approved
TositumomabThe risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.Approved, Investigational
TrapidilTranilast may increase the antiplatelet activities of Trapidil.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Tranilast.Approved, Investigational
TreprostinilTreprostinil may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Tranilast.Approved, Investigational
TriflusalTranilast may increase the antiplatelet activities of Triflusal.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Tranilast.Experimental
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Tranilast.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Tranilast can be decreased when combined with Troleandomycin.Approved
TroxerutinThe risk or severity of bleeding can be increased when Tranilast is combined with Troxerutin.Investigational
TubocurarineTranilast may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Tranilast.Investigational
UrokinaseTranilast may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
VecuroniumTranilast may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tranilast.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Tranilast.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Tranilast.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Tranilast.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the antiplatelet activities of Tranilast.Approved
VoriconazoleThe metabolism of Tranilast can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of adverse effects can be increased when Tranilast is combined with Warfarin.Approved
XimelagatranThe risk or severity of bleeding can be increased when Tranilast is combined with Ximelagatran.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Tranilast.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Tranilast.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Tranilast.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02027
PubChem Compound
5282230
PubChem Substance
99444086
ChemSpider
4445411
BindingDB
21613
ChEBI
77572
ChEMBL
CHEMBL415324
HET
D27
Wikipedia
Tranilast
PDB Entries
2vd0

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentMucinoses1
0Not Yet RecruitingTreatmentSarcoidosis1
0Not Yet RecruitingTreatmentScleredema Adultorum1
1WithdrawnTreatmentRheumatoid Arthritis1
2CompletedTreatmentActive Rheumatoid Arthritis1
2CompletedTreatmentAcute Gouty Arthritis / Hyperuricemia2
3CompletedTreatmentPterygium1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0084 mg/mLALOGPS
logP2.89ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.55ChemAxon
pKa (Strongest Basic)-2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.86 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity91.52 m3·mol-1ChemAxon
Polarizability34.2 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5905
Blood Brain Barrier-0.58
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6922
P-glycoprotein inhibitor INon-inhibitor0.7716
P-glycoprotein inhibitor IINon-inhibitor0.5842
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8054
CYP450 3A4 substrateSubstrate0.5548
CYP450 1A2 substrateNon-inhibitor0.9137
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.9167
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7384
Ames testNon AMES toxic0.6665
CarcinogenicityNon-carcinogens0.871
BiodegradationNot ready biodegradable0.8218
Rat acute toxicity2.4428 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.8008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1900000000-7541d25405a74d897cf6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-2900000000-d54b9ceefe589f6ddc0b

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-cinnamoylanthranilic acids. These are aromatic compounds containing a cinnamic acid conjugated to an anthranilic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid amides
Direct Parent
N-cinnamoylanthranilic acids
Alternative Parents
Acylaminobenzoic acid and derivatives / Dimethoxybenzenes / Anilides / Benzoic acids / Styrenes / Phenoxy compounds / N-arylamides / Anisoles / Benzoyl derivatives / Alkyl aryl ethers
show 8 more
Substituents
N-cinnamoylanthranilic acid / Acylaminobenzoic acid or derivatives / O-dimethoxybenzene / Dimethoxybenzene / Benzoic acid or derivatives / Benzoic acid / Anilide / Phenoxy compound / Anisole / Phenol ether
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dimethoxybenzene, cinnamamides, amidobenzoic acid (CHEBI:77572)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the con...
Gene Name
HPGDS
Uniprot ID
O60760
Uniprot Name
Hematopoietic prostaglandin D synthase
Molecular Weight
23343.65 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Ikai K, Ujihara M, Fujii K, Urade Y: Inhibitory effect of tranilast on prostaglandin D synthetase. Biochem Pharmacol. 1989 Aug 15;38(16):2673-6. [PubMed:2475113]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on September 15, 2010 15:24 / Updated on August 02, 2018 05:52